Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients (Q36028546)

11 August 2017

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients (English)

1 reference

11 August 2017

0 references

1 reference

26

1 reference

11 August 2017

Kiruthikah Thillai

10

0 references

Saif S Ahmad

object named as

Saif S Ahmad

1

0 references

Christian H. Ottensmeier

object named as

Christian H Ottensmeier

28

0 references

Angus Dalgleish

14

object named as

Angus Dalgleish

1 reference

11 August 2017

Wendi Qian

2

1 reference

11 August 2017

Sarah Ellis

3

1 reference

11 August 2017

Elaine Mason

4

1 reference

11 August 2017

Muhammad A Khattak

5

1 reference

11 August 2017

Avinash Gupta

6

1 reference

11 August 2017

Heather Shaw

7

1 reference

11 August 2017

Amy Quinton

8

1 reference

11 August 2017

Jarmila Kovarikova

9

1 reference

11 August 2017

Ankit Rao

11

1 reference

11 August 2017

Ruth Board

12

1 reference

11 August 2017

Jenny Nobes

13

1 reference

11 August 2017

Simon Grumett

15

1 reference

11 August 2017

Anthony Maraveyas

16

1 reference

11 August 2017

Sarah Danson

17

1 reference

11 August 2017

Toby Talbot

18

1 reference

11 August 2017

Mark Harries

19

1 reference

11 August 2017

Maria Marples

20

1 reference

11 August 2017

Ruth Plummer

21

1 reference

11 August 2017

Satish Kumar

22

1 reference

11 August 2017

Paul Nathan

23

1 reference

11 August 2017

Mark R Middleton

24

1 reference

11 August 2017

James Larkin

25

1 reference

11 August 2017

Matthew Wheater

27

1 reference

11 August 2017

Pippa G Corrie

29

1 reference

11 August 2017

language of work or name

English

0 references

publication date

29 July 2015

1 reference

11 August 2017

1 reference

11 August 2017

25

1 reference

11 August 2017

5

1 reference

11 August 2017

432-442

1 reference

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560270

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

21 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26225580

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/CMR.0000000000000185

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

26225580

1 reference